Recent developments in Graves' ophthalmopathy imaging

Journal of Endocrinological Investigation

Volumn 27, Issue 3, 2004, Pages 254-258

  Kahaly, G J ^a,b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Imaging; Thyroid eye disease

Indexed keywords

ANGIOPEPTIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; OCTREOTIDE; PENTETREOTIDE;

ARTICLE; CATARACTOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DECOMPRESSION SURGERY; DIAGNOSTIC ACCURACY; DIPLOPIA; DRUG ACCUMULATION; DRUG EFFICACY; DRUG RESPONSE; DRUG UPTAKE; ECHOOCULOGRAPHY; EDEMA; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EXTRAOCULAR MUSCLE; HUMAN; IMAGE ANALYSIS; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; IONIZING RADIATION; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE DISTRIBUTION; RISK ASSESSMENT; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DIFFERENTIATION;

EID: 2342456316     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345274     Document Type: Article

References (40)

1. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endo Rev 2000, 21: 168-99.
2. Weetman AP, Wiersinga WM. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey. Clin Endocrinol (Oxf) 1998, 49: 21-8
3. Kahaly GJ. New imaging procedures in thyroid-associated ophthalmopathy. Orbit 1996, 15: 165-75.
4. Müller-Forell W, Pitz S, Mann W, Kahaly GJ. Neuroradiological diagnosis of thyroid-associated orbitopathy. Exp Clin Endocrinol Diab 1999, 107: 177-83.
5. Trokel L, Jacobiec FA. Correlation of CT scanning and pathologic features of opthalmic Graves' disease. Ophthalmology 1981, 88: 553-64.
6. Neigel JM, Rootman J, Belkin RI, et al. Dysthyroid optic neuropathy. Ophthalmology 1988, 95 1515-21.
7. Nugent RA, Belkin RI, Neigel JM, et al. Graves' orbitopathy: correlation of CT and clinical findings. Radiology 1990, 177: 675-82.
8. Forbes G, Gorman CA, Gehring D, Baker HL Jr. Computer analysis of orbital fat and muscle volumes in Graves' ophthalmopathy. Am J Neuroradiol 1983, 4: 737-42.
9. Forbes G, Gehring DG, Gorman CA, Brennan MD, Jackson IT. Volume measurements of normal orbital structures by computed tomographic analysis. Am J Neuroradiol 1985, 6: 419-24.
10. Forbes G, Gorman CA, Brennan MD. Ophthalmopathy of Graves' disease: Computerized volume measurements of orbital fat and muscle. Am J Neuroradiol 1986, 7: 651-6.
11. Enzmann DR, Donaldson SS, Kriss JP. Appearance of Graves' disease on orbital computed tomography. J Computed Ass Tomography 1979, 3: 815-9.
12. Yoshikawa K, Higashide T, Nakase Y. Role of rectus muscle enlargement in clinical profile of dysthyroid ophthalmopathy. Jap J Ophthalmol 1991, 35: 175-81.
13. Barret L, Glatt HJ, Burde RM, Gado MH. Optic nerve dysfunction in thyroid eye disease: CT. Radiology 1988, 167: 503-8.
14. Feldon SE, Lee C, Muramatsu S, Weiner J. Quantitative computer tomography of Graves' ophthalmopathy. Arch Ophthalmol 1985, 103: 213-5.
15. Hallin ES, Feldon SE. Graves' ophthalmopathy: II. Correlation of clinical signs with measures derived from computed tomography. Brit J Ophthalmol 1988, 72, 678-82.
16. Just M, Kahaly GJ, Higer HP, et al. Graves' ophthalmopathy: role of MR imaging in radiation therapy. Radiology 1991, 179: 187-90.
17. Hiromatsu Y, Kojima K, Ishisaka N, Tanaka K, Sato M, Nonaka K. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: Its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid 1992, 2: 299-305.
18. Nianiaris N, Hurwitz JJ, Chen JC, Wortzman G. Correlation between computed tomography and magnetic resonance imaging in Graves' orbitopathy. Can J Opthalmol 1994, 29: 9-12
19. Nishikawa M, Yoshimura M, Toyoda N, Masaki H, Yonemoto T, Gondou A. Correlation of orbital muscle changes evaluated by magnetic resonance imaging and thyroid stimulating antibody in patients with Graves' ophthalmopathy. Acta Endocrinol (Copenh) 1993, 129: 213-9.
20. Ohnishi T, Noguchi S, Murakami N, Tajiri J, Harao M, Kawamoto H. Extraocular Muscles in Graves' opthalmopathy: Usefulness of T2 relaxation time measurements. Radiology 1994, 190: 857-62.
21. Utech CI, Khatibnia U, Winter PF, Wulle KG. MR T2 relaxation time for the assessment of retrobulbar inflammation in Graves' ophthalmopathy. Thyroid 1995, 5: 185-93.
22. Kahaly G, Diaz M, Just M, Beyer J, Lieb N. Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy. Thyroid 1995, 5: 107-11.
23. Byrne FS, Gendron E, Glaser J. Diameter of normal extraocular muscles with echography. Am J Ophthalmol 1991, 112: 706-12.
24. Given-Wilson R, Pope RM, Michell MJ, Cannon R, McGregor AM. The use of real/time orbital ultrasound in Graves' ophthalmopathy: a comparison with computer tomography. Brit J Radiol 1989, 62: 705-9.
25. Erickson BA, Harris GJ, Lewandowski MF, Murray KJ, Massaro BM. Echographic monitoring of response of extraocular muscles to irradiation in Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys 1995, 31: 651-60.
26. Prummel M, Suttorp-Schulten M, Wiersinga W, Verbeek A, Mourits M, Koorneef L. A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves' ophthalmopathy. Ophthalmology 1993, 100: 556-61.
27. Nagy EV, Toth J, Kaldi I, Damjanovich J, Meiosi E, Lenkey A. Graves' ophthalmopathy: eye muscle involvement in patients with diplopia. Eur J Endocrinol 2000, 142: 591-7.
28. Demer JL, Kerman BM. Comparison of standardized echography with magnetic resonance imaging to measure extraocular muscle size. Am J Ophthalmol 1994, 118: 351-61.
29. Benning H, Lieb W, Kahaly GJ, Grehn F. Color Doppler ultrasound findings in patients with thyroid ophthalmopathy. Ophthalmologe 1994, 91: 20-5.
30. Krassas GE, Kahaly GJ. The role of octreoscan in thyroid eye disease. Eur J Endocrinol 1999, 140: 373-5.
31. Kahaly G, Diaz M, Hahn K, Beyer J, Bockisch A. Indium 111-Pentetreotide scintigraphy in Graves' ophthalmopathy. J Nucl Med 1995, 36: 550-4.
32. Kahaly G, Görges R, Diaz M, Hommel G, Bockisch A. Indium-111-Pentetreotide in Graves' Disease. J Nucl Med 1998, 39: 533-6.
33. Kahaly GJ, Förster GJ. Somatostatin receptor scintigraphy in thyroid eye disease. Thyroid 1998, 8: 549-52.
34. Postema PTE, Krenning EP, Wijngaarde R, et al. (111-In-DTPA-D-Phe1) octreotide scintigraphy in thyroidal and orbital Graves' disease: A parameter for disease activity? J Clin Endocrinol Metab 1994, 79: 1845-51.
35. Gerding MN, van der Zant FM, van Royen EA, et al. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1999, 50: 373-9.
36. Moncayo R, Baldnisera I, Decristoforo C, Kendler D, Donnemiller E. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using somatostatin analog 111-In-octreotide. Thyroid 1997, 7: 21-9.
37. Krassas GE, Dumas A, Pontikides N, Kaltsas Th. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 1995, 42: 571-80.
38. Krassas GE, Kaltsas Th, Dumas A, Pontikides N, Tolis G. Lanreotide in the treatment of patients with thyroid eye disease. Eur J Endocrinol 1999, 136: 416-22.
39. Förster GJ, Krummenauer F, Nickel O, Kahaly GJ. Somatostatin-receptor scintigraphy in Graves' disease: Reproducibility and inter-/intra-observer variability. Cancer Biother Radiol 2000, 21: 231-6.
40. Förster GJ, Nickel O, Raab D, Andreas J, Kahaly GJ. Somatostatin-receptor scintigraphy in Graves' ophthalmopathy. A new, standardized method for assessement of orbital disease activity. J Nucl Med 1999, 40: 207